Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4640099 | 1.00 | ADRB3 (1.00) | ADRB3ADRB1 | |
| SCHEMBL3873179 | 1.00 | ADRB3 (1.00) | ADRB3ADRB1 | |
| Hydrochloric Acid SCHEMBL4665229 | 0.99 | ADRB3 (0.98) | ADRB3ADRB1 | |
| Hydrochloric Acid SCHEMBL3878377 | 0.99 | ADRB3 (0.98) | ADRB3ADRB1 | |
| Hydrochloric Acid SCHEMBL4639809 | 0.99 | ADRB3 (0.98) | ADRB3ADRB1 | |
| Hydrochloric Acid SCHEMBL4665231 | 0.99 | ADRB3 (0.98) | ADRB3ADRB1 | |
| Hydrochloric Acid SCHEMBL3878376 | 0.99 | ADRB3 (0.98) | ADRB3ADRB1 | |
| Hydrochloric Acid SCHEMBL6133410 | 0.95 | ADRB3 (0.98) | ADRB3ADRB1 | |
| Hydrochloric Acid SCHEMBL6133412 | 0.95 | ADRB3 (0.98) | ADRB3ADRB1 | |
| Hydrochloric Acid SCHEMBL6604673 | 0.95 | ADRB3 (0.98) | ADRB3ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022198259-A1 | TREATMENT METHODS FOR PULMONARY ARTERIAL HYPERTENSION | THE HEART RESEARCH INSTITUTE LTD (AU) | 2022-09-29 | — | — | WO | claimed |
| US-20220034911-A1 | METHOD OF MITIGATION OF DEATH FROM EPILEPTIC SEIZURES | VEGA JOSE (US) | 2022-02-03 | — | — | US | claimed |
| EP-1928448-B1 | ASSOCIATION OF ß3 RECEPTOR AGONIST AND MONOAMINE REUPTAKE INHIBITORS, PHARMACEUTICAL COMPOSITION AND THERAPEUTIC USE THEREOF | SANOFI AVENTIS (FR) | 2009-09-02 | — | — | EP | claimed |
| EP-1404641-B1 | CRYSTALLINE FORM OF A PHENYLETHANOLAMINE, THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | SANOFI AVENTIS (FR) | 2008-08-06 | — | — | EP | claimed |
| US-20080182899-A1 | ASSOCIATION OF BETA3 RECEPTOR AGONIST AND MONOAMINE REUPTAKE INHIBITORS, PHARMACEUTICAL COMPOSITION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2008-07-31 | — | — | US | claimed |
| US-6992211-B2 | Crystalline form of phenylethanolamine, the preparation thereof and pharmaceutical compositions comprising the same | SANOFI-AVENTIS (FR) | 2006-01-31 | — | — | US | claimed |
| US-20040180953-A1 | Crystalline form of phenylethanolamine, the preparation thereof and pharmaceutical compositions comprising the same | SANOFI-AVENTIS (FR) | 2004-09-16 | — | — | US | claimed |
| EP-0626367-B1 | (7S)-7-(1R)-2-(3-chlorophenyl)-2-hydroethylamino-5,6,7,8-tetrahydronaphtalen-2-yloxy acetic acid, their pharmaceutically acceptable salts with a beta-3-adrenergic agonist activity and pharmaceutical compositions containing them | SANOFI SA (FR) | 1997-04-09 | — | — | EP | claimed |
| US-5488151-A | {(7S)-7-[(2R)-2-(3-chlorophenyl)-2-hydroxyethylamino)-2-hydroxyethylamino]5,} acetic acid and its pharmaceutically acceptable salts | SANOFI (FR) | 1996-01-30 | — | — | US | claimed |
| JP-7070013-A | — | — | None | — | — | JP | disclosed |
| JP-7070013-A | — | — | None | — | — | JP | disclosed |
| EP-4638496-A1 | SELECTIVE AND POTENT INHIBITORY ANTIBODIES OF MYOSTATIN ACTIVATION | Scholar Rock, Inc. (US) | 2025-10-29 | — | — | EP | disclosed |
| US-12312599-B2 | Methods, compositions, and kits for producing beige adipocytes and treating metabolic disorders | MaineHealth (US) | 2025-05-27 | — | — | US | disclosed |
| EP-4525833-A2 | VETERINARY PHARMACEUTICAL FORMULATIONS | Increvet, Inc. (US) | 2025-03-26 | — | — | EP | disclosed |
| US-5488151-A | {(7S)-7-[(2R)-2-(3-chlorophenyl)-2-hydroxyethylamino)-2-hydroxyethylamino]5,} acetic acid and its pharmaceutically acceptable salts | SANOFI (FR) | 1996-01-30 | — | — | US | disclosed |
| US-5488151-A | {(7S)-7-[(2R)-2-(3-chlorophenyl)-2-hydroxyethylamino)-2-hydroxyethylamino]5,} acetic acid and its pharmaceutically acceptable salts | SANOFI (FR) | 1996-01-30 | — | — | US | disclosed |
| JP-H0770013-A | ((7S)-7-((2R)-2-(3-CHLOROPHENYL)-2-HYDROXYETHYLAMINO)-5,6,7,8-TETRAHYDRONAPHTHALEN-2-YLOXY)ACETIC ACID AND PHARMACEUTICALLY ACCEPTABLE SALT ACTING AS BETA 3-ADRENERGIC AGONISTS, PHARMACEUTICAL COMPOSITION AND LABORATORY REAGENT IN WHICH IT IS PRESENT | SANOFI SA | 1995-03-14 | — | — | JP | disclosed |
| JP-H0770013-A | ((7S)-7-((2R)-2-(3-CHLOROPHENYL)-2-HYDROXYETHYLAMINO)-5,6,7,8-TETRAHYDRONAPHTHALEN-2-YLOXY)ACETIC ACID AND PHARMACEUTICALLY ACCEPTABLE SALT ACTING AS BETA 3-ADRENERGIC AGONISTS, PHARMACEUTICAL COMPOSITION AND LABORATORY REAGENT IN WHICH IT IS PRESENT | SANOFI SA | 1995-03-14 | — | — | JP | disclosed |
| EP-0627407-A1 | (7S)-7-(2(3-chlorophenyl)-2-hydroethylamino-5,6,7,8-tetrahydro-naphthalen-2-yloxy acetic acid, their pharmaceutically acceptable salts with a beta-3-adrenergic agonist activity and pharmaceutical compositions containing them | MIDY S.p.A. (IT) | 1994-12-07 | — | — | EP | disclosed |
| EP-0626367-A1 | (7S)-7-(1R)-2-(3-chlorophenyl)-2-hydroethylamino-5,6,7,8-tetrahydronaphtalen-2-yloxy acetic acid, their pharmaceutically acceptable salts with a beta-3-adrenergic agonist activity and pharmaceutical compositions containing them | SANOFI (FR) | 1994-11-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080182899-A1 | ASSOCIATION OF BETA3 RECEPTOR AGONIST AND MONOAMINE REUPTAKE INHIBITORS, PHARMACEUTICAL COMPOSITION AND THERAPEUTIC USE THEREOF | ADRB3, ADRB1, ADRB2 | ADRB3 1/4885ADRB1 2/4885 |
| US-12312599-B2 | Methods, compositions, and kits for producing beige adipocytes and treating metabolic disorders | FABP4, LIPC, PNLIP | ADRB3 1065/4885ADRB1 1677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.